Dr. Mitchel A. Kling

powered by
COS Expertise®
University of Pennsylvania
School of Medicine
Psychiatry
Philadelphia VA Medical Center
PhysicianAppointed: 2008
National Institute of Health (NIH)
National Institute of Mental Health
Intramural Research Programs
Developmental Genetic Epidemiology
Special VolunteerAppointed: 2008
Professional Headshot of Mitchel A. Kling

Mailing Address

NIH Bldg. 35 Room 1A-108
Bethesda, Maryland 20892-3720
United States

Contact Information

Phone: (215) 823-5800, ext. 3857
Fax: (215) 823-4123
Mobile: (610) 850-2392
klingm@mail.nih.gov

Qualifications

Residency, University of Pennsylvania, Psychiatry, 1985.
M.D. (Cum Laude), Harvard University, Genetics, 1981.
B.S., Massachusetts Institute of Technology, Applied Biology, 1976.

Expertise and Research Interests

Psychopharmacology of mood and anxiety disorders

Vagus nerve stimulation in treatment-resistant depression and in animal models
Relationship between depression and somatic comorbidity including diabetes, smoking, heart disease, and osteoporosis

Mechanism and treatment of depression induced by therapeutic use of interferons

Thyroid dysfunction in mood disorders and in therapeutic use of psychotropic agents

Role of stress-responsive neurohormonal systems in mood and anxiety disorders

Neurobiology of stress

Other Expertise

Experienced in conducting lumbar punctures and continuous cerebrospinal fluid sampling for neurohormone and metabolite concentrations in neuropsychiatric disorders

Experienced in conducting numerous neuroendocrine challenge paradigms (releasing hormonestimulation testing, pharmacologic challenges with psychotropic agents)

Experienced in designing and conducting polysomnographic and circadian rhythm studies in neuropsychiatric disorders

Future Research

Role of nicotinic receptor mechanisms in mood disorders

Testing of novel treatments for nicotine dependence

Testing of novel treatments for bipolar depression

Effects of vagus nerve stimulation on neural pathways relevant to antidepressant effects in rats

Effects of psychotropic agents on sleep architecture

Behavioral and neuroendocrine mechanisms in metabolic syndrome and type II diabetes

Heart rate variability and autonomic function in mood and anxiety disorders

Industrial Relevance

Development and testing of antidepressive and/or anxiolytic agents, particularly those based on novel mechanisms such as neuropeptide receptor or selective nicotinic receptor actions

Testing of neuroendocrine effects of novel psychotropic agents

Conducting studies of central pharmacokinetics and pharmacodynamics of peripherally-administered drugs using continuous cerebrospinal fluid sampling techniques

Keywords

COS Keywords:

Anxiety Disorders, Neurobiology, Psychiatry, Psychopharmacology, Stress.

Memberships

American Association for the Advancement of Science
American Psychiatric Association
American Society of Clinical Psychopharmacologists
Endocrine Society
International Brain Research Organization
International Neuropeptide Society
Society for Neuroscience
Society of Biological Psychiatry

Previous Positions

1997-2004, Associate Professor, University of Maryland at Baltimore, Medicine, Medicine, Endocrinology, Diabetes, and Nutrition
1996-2004, Associate Professor, University of Maryland at Baltimore, Medicine, Psychiatry
1995-2004, Medical Director, Mood Disorders Program, Baltimore VA Medical Center, Mental Health Service Line, Community Mental Health Subproduct Line
1990-1995, Medical Officer, National Institute of Health (NIH), National Institute of Mental Health, Clinical Neuroendocrinology Branch
1986-1990, Senior Staff Fellow, National Institute of Health (NIH), National Institute of Mental Health, Clinical Neuroendocrinology Branch
1984-1986, Medical Staff Fellow, National Institute of Health (NIH), National Institute of Mental Health, Biological Psychiatry Branch, Section on Clinical Neuroendocrinology

Funding Received

  • Cyberonics, Inc.: Site Primary Investigator, Pivotal Trial of Vagus Nerve Stimulation in Treatment-Resistant Depression (D-02 Study), $500,000, Oct 1, 2000 to Dec 31, 2003.
  • Stanley Medical Research Institute: Effects of transdermal selegiline or oral paroxetine in bipolar depression, $450,000, Aug 1, 2003 to Jul 31, 2006.

Publications

  • Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD, Meyers CA, Howell CD, A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C, Molecular Psychiatry, 7(9), 942-7, 2002 Abstract
  • Kling MA, Carson RE, Borg L, Zametkin A, Matochik JA, Schluger J, Herscovitch P, Rice KC, Ho A, Eckelman WC, Kreek MJ, Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts, Journal of Pharmacology and Experimental Therapeutics, 295(3), 1070-6, December 2000 Abstract
  • Hauser P, Soler R, Reed S, Kane R, Gulati M, Khosla J, Kling MA, Valentine AD, Meyers CA, Prophylactic treatment of depression induced by interferon-alpha, Psychosomatics, 41(5), 439-41, 2000 Abstract
  • Regenold WT, Kling MA, Hauser P, Elevated sorbitol concentration in the cerebrospinal fluid of patients with mood disorders, Psychoneuroendocrinology, 25(6), 593-606, August 2000 Abstract
  • Wong ML, Kling MA, Munson PJ, Listwak S, Licinio J, Prolo P, Karp B, McCutcheon IE, Geracioti TD Jr, DeBellis MD, Rice KC, Goldstein DS, Veldhuis JD, Chrousos GP, Oldfield EH, McCann SM, Gold PW, Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone, Proceedings of the National Academy of Sciences (USA), 97(1), 325-30, Jan 2000 Abstract
  • Tizabi Y, Overstreet DH, Rezvani AH, Louis VA, Clark E Jr, Janowsky DS, Kling MA, Antidepressant effects of nicotine in an animal model of depression, Psychopharmacology, 142(2), 193-9, February 1999 Abstract
  • Ruskin PE, Reed S, Kumar R, Kling MA, Siegel E, Rosen M, Hauser P, Reliability and acceptability of psychiatric diagnosis via telecommunication and audiovisual technology, Psychiatric Services (washington, D.c.), 49(8), 1086-8, August 1998 Abstract
  • Licinio J, Kling MA, Hauser P, Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes, Seminars in Oncology, 25(1 Suppl 1), 30-8, February 1998 Abstract
  • Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P, Mood and cognitive side effects of interferon-alpha therapy, Seminars in Oncology, 25(1 Suppl 1), 39-47, February 1998 Abstract
  • Calogero AE, Scaccianoce S, Burrello N, Nicolai R, Muscolo LA, Kling MA, Angelucci L, D'Agata R, The kappa-opioid receptor agonist MR-2034 stimulates the rat hypothalamic-pituitary-adrenal axis: studies in vivo and in vitro, Journal of Neuroendocrinology, 8(8), 579-85, August 1996 Abstract
  • Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, Sternberg EM, Gold PW, Chrousos GP, Wilder RL, Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia, Arthritis and Rheumatism, 37(11), 1583-92, November 1994 Abstract
  • Kling MA, DeBellis MD, O'Rourke DK, Listwak SJ, Geracioti TD Jr, McCutcheon IE, Kalogeras KT, Oldfield EH, Gold PW, Diurnal variation of cerebrospinal fluid immunoreactive corticotropin-releasing hormone levels in healthy volunteers [published erratum appears in J Clin Endocrinol Metab 1994 Dec, Journal of Clinical Endocrinology and Metabolism, 79(1), 233-9, July 1994 Abstract
  • Kling MA, Gardner DL, Calogero AE, Coppola R, Trettau J, Kellner CH, Lefter L, Hart MJ, Cowdry RW, Post RM, et al, Effects of local anesthetics on experiential, physiologic and endocrine measures in healthy humans and on rat hypothalamic corticotropin-releasing hormone release in vitro: clinical and psychobiologic, Journal of Pharmacology and Experimental Therapeutics, 268(3), 1548-64, March 1994 Abstract
  • De Bellis MD, Chrousos GP, Dorn LD, Burke L, Helmers K, Kling MA, Trickett PK, Putnam FW, Hypothalamic-pituitary-adrenal axis dysregulation in sexually abused girls [see comments], Journal of Clinical Endocrinology and Metabolism, 78(2), 249-55, February 1994 Abstract
  • Kling MA, Smith MA, Glowa JR, Pluznik D, Demas J, DeBellis MD, Gold PW, Schulkin J, Facilitation of cocaine kindling by glucocorticoids in rats, Brain Research, 629(1), 163-6, November 1993 Abstract
  • Kling MA, Demitrack MA, Whitfield HJ Jr, Kalogeras KT, Listwak SJ, DeBellis MD, Chrousos GP, Gold PW, Brandt HA, Effects of the glucocorticoid antagonist RU 486 on pituitary-adrenal function in patients with anorexia nervosa and healthy volunteers: enhancement of plasma ACTH and cortisol secretion in underweight, Neuroendocrinology, 57(6), 1082-91, June 1993 Abstract
  • De Bellis MD, Geracioti TD Jr, Altemus M, Kling MA, Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers, Biological Psychiatry, 33(8-9), 636-41, April 1993 Abstract
  • De Bellis MD, Gold PW, Geracioti TD Jr, Listwak SJ, Kling MA, Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression, American Journal of Psychiatry, 150(4), 656-7, April 1993 Abstract
  • Kling MA, Rubinow DR, Doran AR, Roy A, Davis CL, Calabrese JR, Nieman LK, Post RM, Chrousos GP, Gold PW, Cerebrospinal fluid immunoreactive somatostatin concentrations in patients with Cushing's disease and major depression: relationship to indices of corticotropin-releasing hormone and cortisol secretio, Neuroendocrinology, 57(1), 79-88, January 1993 Abstract
  • Demitrack MA, Gold PW, Dale JK, Krahn DD, Kling MA, Straus SE, Plasma and cerebrospinal fluid monoamine metabolism in patients with chronic fatigue syndrome: preliminary findings, Biological Psychiatry, 32(12), 1065-77, December 1992 Abstract
  • Cizza G, Brady LS, Calogero AE, Bagdy G, Lynn AB, Kling MA, Blackman MR, Chrousos GP, Gold PW, Central hypothyroidism is associated with advanced age in male Fischer 344/N rats: in vivo and in vitro studies, Endocrinology, 131(6), 2672-80, December 1992 Abstract
  • Geracioti TD Jr, Loosen PT, Gold PW, Kling MA, Cortisol, thyroid hormone, and mood in atypical depression: a longitudinal case study, Biological Psychiatry, 31(5), 515-9, March 1992 Abstract
  • Perini GI, Devinsky O, Hauser P, Gallucci WT, Theodore WH, Chrousos GP, Gold PW, Kling MA, Effects of carbamazepine on pituitary-adrenal function in healthy volunteers, Journal of Clinical Endocrinology and Metabolism, 74(2), 406-12, February 1992 Abstract
  • Kling MA, Roy A, Doran AR, Calabrese JR, Rubinow DR, Whitfield HJ Jr, May C, Post RM, Chrousos GP, Gold PW, Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing's disease and major depression: potential clinical implications [see comments], Journal of Clinical Endocrinology and Metabolism, 72(2), 260-71, February 1991 Abstract
  • Kalogeras KT, Calogero AE, Kuribayiashi T, Khan I, Gallucci WT, Kling MA, Chrousos GP, Gold PW, In vitro and in vivo effects of the triazolobenzodiazepine alprazolam on hypothalamic-pituitary-adrenal function: pharmacological and clinical implications, Journal of Clinical Endocrinology and Metabolism, 70(5), 1462-71, May 1990 Abstract

Profile Details

Last Updated: 2/1/2009

COS Expertise ID #835374
Reference this profile directly: http://myprofile.cos.com/mkling